Department of Medical Oncology, GATA Haydarpasa Training Hospital, Haydarpaşa, Istanbul, Turkiye.
Med Oncol. 2010 Jun;27(2):199-202. doi: 10.1007/s12032-009-9191-2. Epub 2009 Mar 5.
To investigate differences of platelet indices in breast cancer patients after tamoxifen (tmx) and anastrazole adjuvant treatment.
In this retrospective study, 46 postmenopausal women (20 with tmx and 26 with anastrazole) with breast cancer who received adjuvant hormone therapy were enrolled. The biochemical and complete blood count (CBC) parameters were documented before hormone treatment start and after 1 year.
The lymphocyte count was higher after tmx use, but not anastrazole. Total white blood cells were increased both after 1-year tmx and anastrazole using. Mean platelet volume (MPV) increased after tmx use (8.2 +/- 0.94-8.97 +/- 0.97; P: 0.041), while it was not different after anastrazole use (7.96 +/- 1.08-7.89 +/- 0.99; P: 0.585). Other platelet parameters did not alter with tmx or anastrazole treatment.
We found increased MPV after tmx treatment, but did not after anastrazole treatment. The advanced studies which explore biological significance of high MPV in breast cancer patients used endocrine therapy, should be established.
研究他莫昔芬（TMX）和阿那曲唑辅助治疗后乳腺癌患者血小板指数的差异。
在这项回顾性研究中，纳入了 46 名接受辅助激素治疗的绝经后乳腺癌女性（TMX 组 20 例，阿那曲唑组 26 例）。记录激素治疗开始前和治疗 1 年后的生化和全血细胞计数（CBC）参数。
TMX 组治疗后淋巴细胞计数较高，但阿那曲唑组无差异。TMX 组和阿那曲唑组治疗 1 年后总白细胞计数均增加。TMX 组治疗后平均血小板体积（MPV）升高（8.2±0.94-8.97±0.97；P：0.041），而阿那曲唑组治疗后无差异（7.96±1.08-7.89±0.99；P：0.585）。其他血小板参数在 TMX 或阿那曲唑治疗后没有改变。
我们发现 TMX 治疗后 MPV 升高，但阿那曲唑治疗后无变化。应该建立进一步的研究来探索接受内分泌治疗的乳腺癌患者中高 MPV 的生物学意义。
Zotero 插件